Non-Hodgkin lymphoma Posts - Page 10 of 44 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

How effective is a modified anti-nausea and vomiting treatment for patients with non-Hodgkin lymphoma undergoing chemotherapy?

How effective is a modified anti-nausea and vomiting treatment for patients with non-Hodgkin lymphoma undergoing chemotherapy?

Posted by on May 17, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of a modified anti-nausea and vomiting treatment for patients with aggressive non-Hodgkin lymphoma (NHL) receiving high-dose (HD) chemotherapy. The results showed that netupitant/palonosetron (NEPA; Akynzeo) alone was very effective and safe for these patients. Some background Chemotherapy...

Read More

Overview of follicular lymphoma treatment

Overview of follicular lymphoma treatment

Posted by on May 10, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This review discussed the treatment of follicular lymphoma (FL).  Some background FL is a cancer of B cells, a type of white blood cell. FL is one of the most common forms of lymphoma. FL is a slow-growing, painless (indolent) cancer that does not always need immediate treatment. Over time, FL can grow more quickly or transform...

Read More

Which chemotherapy combination causes less kidney damage to patients with non-Hodgkin lymphoma?

Which chemotherapy combination causes less kidney damage to patients with non-Hodgkin lymphoma?

Posted by on May 9, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...

Read More

How common are side effects of the heart in patients with non-Hodgkin lymphoma who receive CHOP or R-CHOP chemotherapy?

How common are side effects of the heart in patients with non-Hodgkin lymphoma who receive CHOP or R-CHOP chemotherapy?

Posted by on Apr 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how common side effects of the heart, including heart failure, were among patients with non-Hodgkin lymphoma who received CHOP or R-CHOP chemotherapy. The results showed that only a minority developed side effects and that older patients and female patients were more likely to develop them. Some background Both...

Read More

Do stem cell transplants improve patients’ long-term survival?

Posted by on Apr 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...

Read More

Do stem cell transplants improve patients’ long-term survival?

Posted by on Apr 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...

Read More

How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?

How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?

Posted by on Apr 14, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness and safety of high-dose chemotherapy and stem cell transplants for children with lymphoma. The study showed that the combination treatment was very effective but that the dose may need to be adjusted for some patients. Some background Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have very...

Read More

Does immune cell boosting drug G-CSF reduce the effects of chemotherapy in different cancers?

Does immune cell boosting drug G-CSF reduce the effects of chemotherapy in different cancers?

Posted by on Apr 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effects of granulocyte colony-stimulating factor (G-CSF) given as a preventative measure in patients with high- and medium-risk cancer receiving chemotherapy. The results showed that preventative G-CSF allowed more patients to complete chemotherapy treatment and lowered patients’ chances of developing secondary...

Read More

Monitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma

Monitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Mar 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the activity of two types of asparaginase drugs in pediatric patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma. This study concluded that this type of treatment needs close monitoring for optimal effectiveness. Some background Asparaginase (ASNase) is a drug used in the treatment of...

Read More

Evaluating the risk of infection associated with ibrutinib treatment in patients with B-cell lymphoma

Evaluating the risk of infection associated with ibrutinib treatment in patients with B-cell lymphoma

Posted by on Mar 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma.  This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of...

Read More

Evaluating pembrolizumab plus R-CHOP chemotherapy for patients with untreated diffuse large B-cell lymphoma

Evaluating pembrolizumab plus R-CHOP chemotherapy for patients with untreated diffuse large B-cell lymphoma

Posted by on Mar 10, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that pembrolizumab can be safely added to R-CHOP, with improved survival outcomes. Some...

Read More